<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/9">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/9">
<title>A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial</title>
<dc:title>A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial</dc:title>
<dc:creator>Chaudhry, Imran B</dc:creator>
<dc:creator>Husain, Nusrat</dc:creator>
<dc:creator>ur Rahman, Raza</dc:creator>
<dc:creator>Husain, Mohammed O</dc:creator>
<dc:creator>Hamirani, Mohammed M</dc:creator>
<dc:creator>Kazmi, Ajmal</dc:creator>
<dc:creator>Baig, Shakeel</dc:creator>
<dc:creator>Haddad, Peter M</dc:creator>
<dc:creator>Buch, Maya H</dc:creator>
<dc:creator>Qureshi, Inti</dc:creator>
<dc:creator>Mehmood, Nasir</dc:creator>
<dc:creator>Kiran, Tayyeba</dc:creator>
<dc:creator>Fu, Bo</dc:creator>
<dc:creator>Afsar, Salahuddin</dc:creator>
<dc:creator>Deakin, Bill</dc:creator>
<dc:identifier>info:doi/10.1186/1745-6215-16-9</dc:identifier>
<dc:identifier>info:pmid/25563714</dc:identifier>
<dc:source>Trials 2015, 16:9</dc:source>
<dc:date>2015-01-07</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-01-07</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>9</prism:startingPage>
<prism:copyright>2015 Chaudhry et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Imran B Chaudhry" />
<meta name="citation_author_institution" content="University of Manchester & Lancashire Care Early Intervention Service, Manchester, UK" />
<meta name="citation_author" content="Nusrat Husain" />
<meta name="citation_author_institution" content="University of Manchester & Lancashire Care Early Intervention Service, Manchester, UK" />
<meta name="citation_author" content="Raza ur Rahman" />
<meta name="citation_author_institution" content="Dow University of Health Sciences, Karachi, Pakistan" />
<meta name="citation_author" content="Mohammed O Husain" />
<meta name="citation_author_institution" content="Southwest London and St George’s NHS Trust, London, UK" />
<meta name="citation_author" content="Mohammed M Hamirani" />
<meta name="citation_author_institution" content="Abbassi Shaheed Hospital, Karachi, Pakistan" />
<meta name="citation_author" content="Ajmal Kazmi" />
<meta name="citation_author_institution" content="Pakistan Institute of Leaning and Living, Karachi, Pakistan" />
<meta name="citation_author" content="Shakeel Baig" />
<meta name="citation_author_institution" content="Baqai University, Karachi, Pakistan" />
<meta name="citation_author" content="Peter M Haddad" />
<meta name="citation_author_institution" content="University of Manchester & Greater Manchester West Mental Health NHS Foundation Trust, Manchester, UK" />
<meta name="citation_author" content="Maya H Buch" />
<meta name="citation_author_institution" content="University of Leeds, Leeds, UK" />
<meta name="citation_author" content="Inti Qureshi" />
<meta name="citation_author_institution" content="Mersey Care NHS Trust, Liverpool, UK" />
<meta name="citation_author" content="Nasir Mehmood" />
<meta name="citation_author_institution" content="Pakistan Institute of Leaning and Living, Karachi, Pakistan" />
<meta name="citation_author" content="Tayyeba Kiran" />
<meta name="citation_author_institution" content="Pakistan Institute of Leaning and Living, Karachi, Pakistan" />
<meta name="citation_author" content="Bo Fu" />
<meta name="citation_author_institution" content="University of Manchester, Manchester, UK" />
<meta name="citation_author" content="Salahuddin Afsar" />
<meta name="citation_author_institution" content="Dow University of Health Sciences, Karachi, Pakistan" />
<meta name="citation_author" content="Bill Deakin" />
<meta name="citation_author_institution" content="University of Manchester, Manchester, UK" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-01-07" />
<meta name="citation_firstpage" content="9" />
<meta name="citation_doi" content="10.1186/1745-6215-16-9" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/1745-6215-16-9.pdf" />
<meta name="citation_pmid" content="25563714" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/1745-6215-16-9.pdf" />
<meta name="title" content="A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial" />
<meta name="description" content="Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory drug) for 1&nbsp;year to treatment as usual reduced negative symptoms and improved some cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of schizophrenia because their levels were elevated during acute exacerbations and reduced in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia. Based on the evidence of the strong anti-inflammatory properties of methotrexate, we propose that low-dose methotrexate may be an effective therapy in early schizophrenia." />

<meta name="dc.title" content="A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Chaudhry, Imran B" />
<meta name="dc.creator" content="Husain, Nusrat" />
<meta name="dc.creator" content="ur Rahman, Raza" />
<meta name="dc.creator" content="Husain, Mohammed O" />
<meta name="dc.creator" content="Hamirani, Mohammed M" />
<meta name="dc.creator" content="Kazmi, Ajmal" />
<meta name="dc.creator" content="Baig, Shakeel" />
<meta name="dc.creator" content="Haddad, Peter M" />
<meta name="dc.creator" content="Buch, Maya H" />
<meta name="dc.creator" content="Qureshi, Inti" />
<meta name="dc.creator" content="Mehmood, Nasir" />
<meta name="dc.creator" content="Kiran, Tayyeba" />
<meta name="dc.creator" content="Fu, Bo" />
<meta name="dc.creator" content="Afsar, Salahuddin" />
<meta name="dc.creator" content="Deakin, Bill" />
<meta name="dc.description" content="Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory drug) for 1&nbsp;year to treatment as usual reduced negative symptoms and improved some cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of schizophrenia because their levels were elevated during acute exacerbations and reduced in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia. Based on the evidence of the strong anti-inflammatory properties of methotrexate, we propose that low-dose methotrexate may be an effective therapy in early schizophrenia." />
<meta name="dc.source" content="Trials 2015 16:9" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-01-07" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/1745-6215-16-9" />
<meta name="dc.identifier" content="info:pmid/25563714" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Chaudhry et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-01-07" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="9" />
<meta name="prism.copyright" content="2015 Chaudhry et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/9/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/9" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/1745-6215-16-9.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/1745-6215-16-9-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/1745/6215/16/9";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/1745/6215/16/9</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/1745/6215/16/9/15125551158@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/1745/6215/16/9/17068121763@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/Design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li>
      <a href="#ack">Acknowledgments</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/pdf/1745-6215-16-9.pdf">PDF</a>
			<span>(288KB)</span>
		</li>

        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                        <li>
            <a onclick="_gaq.push(['_trackEvent', 'Pubmed record', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/pubmed/25563714">PubMed record</a>
        </li>
                            <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.trialsjournal.com/content/16/1/9/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22A+randomised+double-blind+placebo-controlled+12-+week+feasibility+trial+of+methotrexate+added+to+treatment+as+usual+in+early+schizophrenia%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22IB+Chaudhry%22">Chaudhry IB</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22N+Husain%22">Husain N</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+ur Rahman%22">ur Rahman R</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22MO+Husain%22">Husain MO</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22MM+Hamirani%22">Hamirani MM</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22A+Kazmi%22">Kazmi A</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22S+Baig%22">Baig S</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22PM+Haddad%22">Haddad PM</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22MH+Buch%22">Buch MH</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22I+Qureshi%22">Qureshi I</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22N+Mehmood%22">Mehmood N</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22T+Kiran%22">Kiran T</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22B+Fu%22">Fu B</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22S+Afsar%22">Afsar S</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22B+Deakin%22">Deakin B</a>
            </li>
            </ul>          </li>
                <li>
            		<a class="collapser"><i>&nbsp;</i>on PubMed</a>
	<ul id="authpm" class="hidebeforeload"> 									<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chaudhry_IB%20[Author]">Chaudhry IB</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Husain_N%20[Author]">Husain N</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=ur_Rahman_R%20[Author]">ur Rahman R</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Husain_MO%20[Author]">Husain MO</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hamirani_MM%20[Author]">Hamirani MM</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kazmi_A%20[Author]">Kazmi A</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Baig_S%20[Author]">Baig S</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Haddad_PM%20[Author]">Haddad PM</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Buch_MH%20[Author]">Buch MH</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Qureshi_I%20[Author]">Qureshi I</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mehmood_N%20[Author]">Mehmood N</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kiran_T%20[Author]">Kiran T</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Fu_B%20[Author]">Fu B</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Afsar_S%20[Author]">Afsar S</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Deakin_B%20[Author]">Deakin B</a>
				</li>
						</ul > 	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/9">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/9">on Google Scholar</a></li>
                    <li><a onclick="_gaq.push(['_trackEvent', 'on Pubmed', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/pubmed/related/25563714">on PubMed</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/download/xml/1745-6215-16-9.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/1745-6215-16-9&volume=16&issue=1&title=A+randomised+double-blind+placebo-controlled+12-+week+feasibility+trial+of+methotrexate+added+to+treatment+as+usual+in+early+schizophrenia%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Imran B Chaudhry&start_page=1&end_page=9">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F9" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/9', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/9" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/9', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F9" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/9', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/9" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/9', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/9', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/9" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/9" data-counturl="http://www.trialsjournal.com/content/16/1/9" data-hashtags="trials
" data-text="A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/9', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/9"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/9"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AA%20randomised%20double-blind%20placebo-controlled%2012-%20week%20feasibility%20trial%20of%20methotrexate%20added%20to%20treatment%20as%20usual%20in%20early%20schizophrenia%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F9&title=A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/9&title=A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="/content/16/1/9/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/9"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/9"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/9', 1, true]);" href="http://twitter.com/?status=A%20randomised%20double-blind%20placebo-controlled%2012-%20week%20feasibility%20trial%20of%20methotrexate%20added%20to%20treatment%20as%20usual%20in%20early%20schizophrenia%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F9+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/9'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/1745/6215/16/9/12968541355@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/1745/6215/16/9/11820208582@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
			<a href="http://www.biomedcentral.com/about/mostviewed/"><img alt="Highly Accessed" src="/images/articles/highlyaccessed-large.png" class="access mr15"/></a>
				<span class="articletype">Study protocol</span>

<h1>A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												         <strong>Imran B Chaudhry</strong><sup><a href="/content/16/1/9/#ins1">1</a></sup><sup>&#42;</sup>, <strong>Nusrat Husain</strong><sup><a href="/content/16/1/9/#ins1">1</a></sup>, <strong>Raza ur Rahman</strong><sup><a href="/content/16/1/9/#ins2">2</a></sup>, <strong>Mohammed Omair Husain</strong><sup><a href="/content/16/1/9/#ins3">3</a></sup>, <strong>Mohammed M Hamirani</strong><sup><a href="/content/16/1/9/#ins4">4</a></sup>, <strong>Ajmal Kazmi</strong><sup><a href="/content/16/1/9/#ins5">5</a></sup>, <strong>Shakeel Baig</strong><sup><a href="/content/16/1/9/#ins6">6</a></sup>, <strong>Peter M Haddad</strong><sup><a href="/content/16/1/9/#ins7">7</a></sup>, <strong>Maya H Buch</strong><sup><a href="/content/16/1/9/#ins8">8</a></sup>, <strong>Inti Qureshi</strong><sup><a href="/content/16/1/9/#ins9">9</a></sup>, <strong>Nasir Mehmood</strong><sup><a href="/content/16/1/9/#ins5">5</a></sup>, <strong>Tayyeba Kiran</strong><sup><a href="/content/16/1/9/#ins5">5</a></sup>, <strong>Bo Fu</strong><sup><a href="/content/16/1/9/#ins10">10</a></sup>, <strong>Salahuddin Afsar</strong><sup><a href="/content/16/1/9/#ins2">2</a></sup> and <strong>Bill Deakin</strong><sup><a href="/content/16/1/9/#ins10">10</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Imran B Chaudhry <a href='mailto:ibchaudhry@btinternet.com'>ibchaudhry@btinternet.com</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                University of Manchester & Lancashire Care Early Intervention Service, Manchester, UK
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Dow University of Health Sciences, Karachi, Pakistan
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Southwest London and St George’s NHS Trust, London, UK
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Abbassi Shaheed Hospital, Karachi, Pakistan
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                Pakistan Institute of Leaning and Living, Karachi, Pakistan
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Baqai University, Karachi, Pakistan
                            </p>
																    						    <p >
						        <sup id="ins7">7</sup>                                University of Manchester & Greater Manchester West Mental Health NHS Foundation Trust, Manchester, UK
                            </p>
																    						    <p >
						        <sup id="ins8">8</sup>                                University of Leeds, Leeds, UK
                            </p>
																    						    <p >
						        <sup id="ins9">9</sup>                                Mersey Care NHS Trust, Liverpool, UK
                            </p>
																    						    <p >
						        <sup id="ins10">10</sup>                                University of Manchester, Manchester, UK
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:9&nbsp;
			<span class="pseudotab">doi:10.1186/1745-6215-16-9</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/9">http://www.trialsjournal.com/content/16/1/9</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>20 May 2014</td></tr>                <tr><td>Accepted:</td><td>16 December 2014</td></tr>        <tr><td>Published:</td><td>7 January 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Chaudhry et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There
         is growing evidence that inflammatory processes are involved in the pathogenesis of
         schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial
         in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory
         drug) for 1&nbsp;year to treatment as usual reduced negative symptoms and improved some
         cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has
         identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of
         schizophrenia because their levels were elevated during acute exacerbations and reduced
         in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia.
         Based on the evidence of the strong anti-inflammatory properties of methotrexate,
         we propose that low-dose methotrexate may be an effective therapy in early schizophrenia.
      </p>
      <h4>Methods/Design</h4>
      <p style="line-height:160%">This is a double-blind placebo-controlled study of methotrexate added to treatment
         as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis
         not otherwise specified or schizophreniform disorder. This will be with 72 patients,
         36 in each arm over 3&nbsp;months. There will be screening, randomisation and follow-up
         visits. Full clinical assessments will be carried out at baseline, 2, 4, 8 and 12&nbsp;weeks.
         Social and cognitive assessments will be carried out at baseline and 12&nbsp;weeks. Methotrexate
         will be given at a dose of 10 mgs orally once a week for a 3-month period.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia
         and anti-inflammatory treatments have shown to have some beneficial effects. Methotrexate
         is a known immunosuppressant and anti-inflammatory drug. The aim of this study is
         to establish the degree of improvement in positive and negative symptoms, as well
         as cognitive functioning with the addition of methotrexate to treatment as usual.
      </p>
      <p style="line-height:160%">ClinicalTrials.gov identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT02074319">NCT02074319</a> (24 February 2014).
      </p>
   </div>
</section>
<section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Methotrexate (MXTis a commonly used anti-inflammatory and immunosuppressive drug,
         originally developed and continuing to be used for chemotherapy either alone or in
         combination with other agents. It is used as a treatment for some autoimmune diseases,
         including arthritis, psoriasis, psoriatic arthritis, lupus and Crohn's disease. Low-dose
         MXT has been used for treatment of rheumatoid arthritis for almost 50&nbsp;years, is very
         effective and is recognised as treatment of choice and first-line therapy for many
         patients 
         				<a name="d75316e270"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. MXT is thought to affect cancer and rheumatoid arthritis by two different pathways.
         For cancer, MXT competitively inhibits dihydrofolate reductase (DHFR), an enzyme that
         participates in the tetrahydrofolate synthesis 
         				<a name="d75316e274"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]. However, in rheumatoid arthritis it most likely acts by the inhibition of enzymes
         involved in purine metabolism or by inhibition of T cell activation 
         				<a name="d75316e278"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>].
      </p>
      <p style="line-height:160%">There has been interest in using MXT in other conditions where excessive immune activation
         and inflammatory mediators are believed to be involved in the pathogenesis. For example,
         Gong <em>et al</em>. 
         				<a name="d75316e287"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>] showed that in cardiac failure patients, low-dose MXT has significant anti-inflammatory
         effects and improved functional outcomes and quality of life. In an animal model of
         cardiac failure Zhang <em>et al</em>. 
         				<a name="d75316e294"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>] showed that MXT has the ability to regulate inflammatory responses and improve cardiac
         function, hence contributing to prevent the development of post-myocarditis dilated
         cardiomyopathy.
      </p>
      <p style="line-height:160%">There is growing evidence that inflammatory processes are involved in the pathogenesis
         of schizophrenia 
         				<a name="d75316e300"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>]. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan
         and Brazil, funded by the Stanley Medical Research Institute (SMRI), the addition
         of minocycline (an antibiotic and anti-inflammatory drug) for 1&nbsp;year to treatment
         as usual (TAU) reduced negative symptoms and improved some cognitive measures 
         				<a name="d75316e304"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>]. Several studies have noted increase in peripheral inflammatory cytokines, such as
         IL-1, IL-2, IL-6, and TNF-alpha 
         				<a name="d75316e308"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. In the brain, cytokines seem to be involved in regulating the action of several
         neurotransmitters, such as serotonin, noradrenalin, dopamine, and glutamate. The interaction
         of cytokines with dopamine and glutamate seems to be especially relevant to the pathophysiology
         of schizophrenia 
         				<a name="d75316e312"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>].
      </p>
      <p style="line-height:160%">A meta-analysis of cytokine changes in the peripheral blood has identified IL-12,
         IFN-gamma, TNF-alpha, and soluble IL-2 receptor (sIL-2R) as trait markers of schizophrenia
         because their levels were elevated during acute exacerbations and remission 
         				<a name="d75316e318"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. An extensive meta-analysis by Potvin <em>et al</em>. 
         				<a name="d75316e325"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>] reports significant increases in <em>in vivo</em> peripheral levels of IL-1RA, sIL-2R, and IL-6 in schizophrenia patients, supporting
         evidence of immune activation and an inflammatory syndrome in schizophrenia. Studies
         show that IL-6 mediates the deleterious effects of noncompeting N-methyl-D-aspartate
         (NMDA) antagonists on cortical interneurons 
         				<a name="d75316e332"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>] and cytokines have an impact on the regulation of neuroplasticity, cellular resilience,
         and apoptosis control 
         				<a name="d75316e337"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. TNF-alpha seems to inhibit brain-derived neurotrophic factor (BDNF) release, compromising
         the protective effect of this neurotrophin.
      </p>
      <p style="line-height:160%">A number of studies report that treatment with antipsychotic drugs affects the cytokine
         network 
         				<a name="d75316e343"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]. This supports the rationale that the influence of antipsychotics on the cytokine
         systems may be responsible for their clinical efficacy in schizophrenia. Peripheral
         immune processes may be mirrored in the brain by microglial cells 
         				<a name="d75316e347"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>]. The 'microglia hypothesis of schizophrenia' suggests that the release of proinflammatory
         cytokines, kynurenines, nitric oxide (NO) and reactive oxygen species (ROS) by activated
         microglia might cause neuronal degeneration, white matter abnormalities and decreased
         neurogenesis 
         				<a name="d75316e351"></a><a name="d75316e353"></a><a name="d75316e355"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>-<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. Recent positron emission tomography (PET) studies during acute psychotic episodes
         in early schizophrenia suggest an activation of microglia 
         				<a name="d75316e359"></a><a name="d75316e361"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a></a>,<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>].
      </p>
      <p style="line-height:160%">If MXT, which is already on the market for the treatment of heart disease, cancer
         and rheumatic diseases, proves effective for reducing symptoms of schizophrenia then
         this could transform the suffering evidenced by patients which severely impairs their
         quality of life. Targeting the inflammatory response is a major focus of novel drug
         development especially relevant to the treatment of Treatment Resistant Schizophrenia
         (TRS). Based on the evidence of strong anti-inflammatory properties of MXT, we propose
         that low-dose MXT may be an effective therapy in early schizophrenia.
      </p>
      <h4>AIMS</h4>
      <p style="line-height:160%">To test the prediction that addition of MXT to treatment as usual (TAU) for patients
         with early schizophrenia will result in following outcomes:
      </p>
      <p style="line-height:160%" class="xfullindent1"><span class="monospace">○</span> To demonstrate that the trial design is acceptable to participants including randomisation
         to x arms
      </p>
      <p style="line-height:160%" class="xfullindent1"><span class="monospace">○</span> To demonstrate that the interventions are acceptable to participants and indicate
         likely attrition rates and tolerabilityImprovement in negative symptoms
      </p>
      <p style="line-height:160%" class="xfullindent1"><span class="monospace">○</span> Improvement in positive symptoms
      </p>
      <p style="line-height:160%" class="xfullindent1"><span class="monospace">○</span> Improvement in social functioning
      </p>
      <p style="line-height:160%" class="xfullindent1"><span class="monospace">○</span> Improvement in cognitive functions
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/Design</h3>
   <div class="collapsible-content">
      <h4>Overview</h4>
      <p style="line-height:160%">This is a double-blind placebo-controlled trial of MXT added to TAU for patients suffering
         from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or
         schizophreniform disorder. The ethical approval covering all sites was obtained from
         the Research and Ethics Committee of the Pakistan Institute of Learning and Living
         and was submitted to the funding body, SMRI (Project Reference: PILL/SMRI/12627).
         Patients will be recruited from inpatient and outpatient settings. They will initially
         be approached by the treating psychiatrists and the multi-disciplinary teams (MDT).
         Patients will continue to take TAU during the trial. Although, the study assessments
         will be carried out by the research assistants (RAs), the responsible clinician (consultant
         psychiatrist) will remain in charge of the overall treatment. Antipsychotic dosage
         will be kept constant, unless clinically warranted, any changes will be recorded on
         monthly reviews.
      </p>
      <p style="line-height:160%">After consenting to take part in the study, 72 patients will be randomised into two
         groups: 36 in each arm over the 3-month period. Full clinical assessments will be
         carried out at baseline, 2, 4, 8 and 12&nbsp;weeks. Social and cognitive assessments will
         be carried out at baseline and 12&nbsp;weeks (Table&nbsp;
         					<a name="d75316e404"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/9/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/9/table/T1">1</a>). MXT once a week or placebo once a week will be added to TAU. Tolerability will
         be assessed by self report. During the course of the study the patient will also have
         additional support by doctors and RAs from the research team and continued support
         from their mental health care team. If necessary, members of the research team will
         be available 24&nbsp;hours a day, 7&nbsp;days a week.
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/9/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/9/table/T1"><strong>Table 1.</strong></a> <strong>Schedule of assessments</strong></div></div>
      <h4>Allocation</h4>
      <p style="line-height:160%">In this study patients will be allocated to treatment group according to a randomised
         permuted blocks algorithm, after stratification by centre. Allocation will be determined
         in Manchester by pseudo-random number generation by the trial statistician. The results
         will be conveyed to the trial pharmacist so that medication can be given to participants
         without anyone else on the team being aware of the allocation (that is, double-blind).
      </p>
      <h4>Blinding</h4>
      <p style="line-height:160%">This is a double-blind, randomised, placebo-controlled feasibility study. Random allocation
         to treatments will be undertaken by a statistician who will have no knowledge of the
         patient characteristics. The details of the allocation will be concealed from the
         research team until all data collection has been completed. Blinding of participants
         and treating physicians to allocation status will be assured by identical capsule
         appearance, by identical labelling between placebo and the active drugs (apart from
         labels identifying the patient). Blinding of the capsules, packaging and labelling,
         will be undertaken by pharmacist independent of the study. Study investigators and
         researchers administering the assessment measures will not be aware of the study drug
         allocated to the individual. In the event a patient develops any side- effects, where
         drug unblinding is required, the treating physician will be made aware of the study
         drug, possible side-effects and make the appropriate decision whether to continue
         or discontinue the drug. The safety and wellbeing of the patient will be paramount
         at all times.
      </p>
      <h4>Statistical consideration</h4>
      <p style="line-height:160%">Our sample size consideration is based on the hypothesis that there will be a significant
         difference in changes from baseline to end-point on the clinical outcome measures
         and the cognitive function measures between the MXT group and the TAU group. With
         32 participants per group, this study will have 80% power to detect a standardised
         effect size of 0.53 (medium by the definition of Cohen) by using a 2-sided significant
         level of 0.20. As this is a preliminary study, we used a less stringent significance
         level so as not to miss a promising effect rather than being too concerned by false
         positives. The estimated loss to follow-up rate is 10% and, therefore, a total of
         72 patients (36 MXT, 36 TAU) are needed. Our sample size is adequate to estimate the
         parameters of acceptability and tolerability to the necessary degree of precision.
      </p>
      <p style="line-height:160%">The planned analyses will be by intention-to-treat (ITT). Careful consideration will
         be given to the potential biases arising from the drop-out and missing data. Group
         differences in the change of clinical outcome measures and cognitive function measures
         at baseline to 12&nbsp;weeks will be assessed using the <em>t</em>-test or analysis of covariance (ANCOVA) adjusting for baseline differences. For repeatedly
         measured clinical outcomes at baseline, 2, 4, 8 and 12&nbsp;weeks, we will also use generalised
         estimating equations (GEE) to estimate the effect of MXT treatment on longitudinal
         outcomes, including baseline values and time terms as covariates. GEE offers a robust
         method to take account of the within-subject correlation in longitudinal data.
      </p>
      <h4>Inclusion/Exclusion criteria</h4>
      <h4>Inclusion criteria</h4>
      <p style="line-height:160%" class="xfullindent1">• Signed informed consent, indicating that the subject understood the purpose of and
         procedures required for the study, before the initiation of any study specific procedures
      </p>
      <p style="line-height:160%" class="xfullindent1">• Aged 18 to 35&nbsp;years</p>
      <p style="line-height:160%" class="xfullindent1">• <em>Diagnostic and Statistical Manual-IV</em> (DSM-IV) diagnosed schizophrenia, schizoaffective disorder, psychosis not otherwise
         specified or schizophreniform disorder
      </p>
      <p style="line-height:160%" class="xfullindent1">• Early schizophrenia (within first 5&nbsp;years of diagnosis)</p>
      <p style="line-height:160%" class="xfullindent1">• Competent and willing to give informed consent</p>
      <p style="line-height:160%" class="xfullindent1">• Medication remained stable 4&nbsp;weeks prior to baseline</p>
      <p style="line-height:160%" class="xfullindent1">• Able to take oral medication and likely to complete the required evaluations</p>
      <p style="line-height:160%" class="xfullindent1">• Female participants of child-bearing capability must be willing to use adequate
         contraceptives for the duration of the study, and willing to have a pregnancy test
         pre- treatment and at 10-weekly intervals while on study medication. Adequate contraception
         is defined as use of contraceptive double barrier system (that is condom and spermicide)
         or contraceptive implant, oral contraceptive or injected depot contraceptive plus
         other form of contraceptive, that is a condom. Females will be considered incapable
         of child-bearing if they are 1&nbsp;year post-menopausal or irreversibly surgically sterilised
      </p>
      <h4>Exclusion criteria</h4>
      <p style="line-height:160%" class="xfullindent1">• Violation of any inclusion criteria</p>
      <p style="line-height:160%" class="xfullindent1">• Failure to perform screening or baseline examinations</p>
      <p style="line-height:160%" class="xfullindent1">• Relevant <em>International Statistical Classification of Diseases and Related Health Problems</em> (ICD-10) organic brain disease or neurological diagnoses (including electrocardiogram
         (ECG) conduction abnormalities, neurological disorder, or an active seizure)
      </p>
      <p style="line-height:160%" class="xfullindent1">• Patients with liver disease and polyarthritis</p>
      <p style="line-height:160%" class="xfullindent1">• Patients who will meet the criteria for a DSM-IV-text revision(TR) diagnosis of
         alcohol or substance abuse (other than for nicotine) within the last month or the
         criteria for DSM-IV-TR alcohol or substance dependence (other than for nicotine) within
         the last 6&nbsp;months
      </p>
      <p style="line-height:160%" class="xfullindent1">• Any change of psychotropic medications within the previous 4&nbsp;weeks</p>
      <p style="line-height:160%" class="xfullindent1">• Pregnant or lactating women and those of reproductive age without adequate contraception</p>
      <p style="line-height:160%" class="xfullindent1">• Relevant medical illness will be determined in the first instance by asking the
         patient's mental health care team if the patient has any medical condition/problems.
         After consent has been obtained the research nurse/research doctor will then have
         access to the patients’ notes and will assess patient eligibility to take part in
         the clinical trial by scrutinising the patients’ past medical history, most recent
         blood results, ECGs, as well as any physical tests that have been performed on the
         patient. If there are any deviations from the ‘norm’ the investigators will assess
         the eligibility of the individual patient. Automatic contraindications will include
         significantly impaired renal function, significantly impaired hepatic function and
         pre-existing blood dyscrasias, such as significant marrow hypoplasia, leukopenia,
         thrombocytopenia or anemia.
      </p>
      <h4>Interval of assessments</h4>
      <p style="line-height:160%">There will be a screening, a randomisation and follow-up visits. Full clinical assessments
         (Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Global
         Assessment of Functioning (GAF), Social Functioning Scale (SFS) and Quality of Life
         Scale (QLS)) will be carried out at baseline, 2, 4, 8 and 12&nbsp;weeks. Social and cognitive
         assessments (CogState, IQ using Wechsler Adult Intelligence Scale (WAIS) block design,
         Coughlan Learning Task, Stroop Task, Verbal Fluency) will be carried out at baseline
         and 12&nbsp;weeks. The clinical interview and ratings will take approximately 50&nbsp;minutes.
         The neuropsychological assessments will take about 60 to 80&nbsp;minutes. The patients
         will primarily be seen at their treating team’s base. In special circumstances, if
         requested by the treating team or patient, the RAs can visit at home.
      </p>
      <h4>RA training and inter-rater reliability</h4>
      <p style="line-height:160%">Research assistants in Karachi were trained in Structured Clinical Interview for DSM-IV
         (SCID), clinical and neuropsychological assessments at the University of Manchester
         for a previous SMRI-funded study. Inter-rater reliability sessions will be conducted
         by local principle investigators (PIs) using training videos.
      </p>
      <h4>Treatments</h4>
      <h4>Treatment as usual</h4>
      <p style="line-height:160%">The patients can be on either first or second generation antipsychotic medications,
         as deemed suitable by the responsible psychiatrist. From our experience with previous
         studies there is no major advantage of one generation of drugs over the other.
      </p>
      <h4>Study drug dosage</h4>
      <p style="line-height:160%">MXT 7.5 mgs orally once a week) for a 3-month period as an augmentation agent with
         TAU. All participants will also take folic acid 5 mgs/day orally for 6&nbsp;days a week
         (except the day MXT is given), which is routinely given with MXT to prevent vitamin
         deficiencies.
      </p>
      <h4>Outcome measures for tolerability and acceptability</h4>
      <p style="line-height:160%">The definition of tolerability refers to adverse events. An adverse event is the development
         of an undesirable medical condition or the deterioration of a pre-existing medical
         condition following or during exposure to a pharmaceutical product, whether or not
         considered causally related to the product.
      </p>
      <p style="line-height:160%">At each clinical assessment (baseline, 2, 4, 8 and 12&nbsp;weeks and early exit from the
         study) we will collect spontaneously reported adverse effects and also administer
         an adverse effect check list covering 8 key symptoms/signs of MXT toxicity (rash,
         oral ulceration, nausea and vomiting, diarrhea, new or increasing dyspnea, new or
         increasing dry cough, severe sore throat, abnormal bruising). If any of these eight
         symptoms are present MXT will be withheld until the case has been discussed with the
         onsite investigator. In addition, severe sore throat or abnormal bruising will lead
         to an urgent full blood count (FBC) being conducted, the result of which will be considered
         by the investigator in reaching a decision on the patient continuing in the trial.
         The routine blood tests at baseline, 2, 4, 6 and 12&nbsp;weeks will be reviewed by the
         site investigator within 4&nbsp;days of being taken and the patient withdrawn from the
         study if any indices give cause for concern (that is are outside pre-specified parameters).
      </p>
      <p style="line-height:160%">Acceptability is defined as treatment discontinuation in terms of the number of patients
         who terminated the study early (drop-outs) for any reason following randomisation.
         We will request an exit interview with all participants who did not complete the study
         to explore tolerability and acceptability.
      </p>
      <h4>Clinical outcome measures</h4>
      <p style="line-height:160%" class="xfullindent1">1. Negative symptom severity as defined by negative syndrome subscale score on the
         PANSS and/or Negative Symptom Assessment Scale;
      </p>
      <p style="line-height:160%" class="xfullindent1">2. Full PANSS and positive syndrome subscale score 
         					<a name="d75316e1138"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]
      </p>
      <p style="line-height:160%" class="xfullindent1">3. CGI</p>
      <p style="line-height:160%" class="xfullindent1">4. Functional outcome:</p>
      <p style="line-height:160%" class="xfullindent1">• GAF from DSM-IV (2000) 
         					<a name="d75316e1147"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>]
      </p>
      <p style="line-height:160%" class="xfullindent1">• SFS self-rating in seven domains 
         					<a name="d75316e1152"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>]
      </p>
      <p style="line-height:160%" class="xfullindent1">• QLS for treatment effects related to deficit or negative symptoms 
         					<a name="d75316e1157"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>]
      </p>
      <h4>Cognitive function measures</h4>
      <p style="line-height:160%">We will use pencil and paper tests and CogState; measuring all seven domains recommended
         by MATRICS (NIMH initiative). These domains include speed processing, attention/vigilance,
         working memory (nonverbal and verbal), verbal learning, visual learning, reasoning
         and problem solving and social cognitions. We will use the following tests:
      </p>
      <p style="line-height:160%" class="xfullindent1">1. IQ: using WAIS block design</p>
      <p style="line-height:160%" class="xfullindent1">2. Stroop Task, for divided attention and processing speed</p>
      <p style="line-height:160%" class="xfullindent1">3. Coughlan Learning Task (Verbal and Visual)</p>
      <p style="line-height:160%" class="xfullindent1">4. Verbal Fluency (words and categories)</p>
      <h4>Side-effects</h4>
      <p style="line-height:160%">Self reported antipsychotic side-effects: Antipsychotic Non-Neurological Side-Effects
         Rating Scale (ANNSERS) 
         					<a name="d75316e1180"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>].
      </p>
      <h4>Safety assessments</h4>
      <h4>Medical history</h4>
      <p style="line-height:160%">The primary purpose of screening is to check for inclusion and exclusion criteria.
         The RAs will arrange for a doctor to complete checklists for medical history, review
         of systems and physical exam. These assessments will be repeated after 3&nbsp;months in
         the trial or at the time of withdrawal from the study.
      </p>
      <h4>Physical assessments</h4>
      <p style="line-height:160%">ECG, blood pressure, pulse, height, waist, weight and body mass index (BMI).</p>
      <h4>Blood investigations</h4>
      <p style="line-height:160%">FBC, erythrocyte sedimentation rate, LFTs, lipid profile, urea, electrolytes, cytokines
         and C-reactive protein.
      </p>
      <p style="line-height:160%">Patients will have FBC and renal and LFTs before starting treatment and repeated at
         2, 4, 6 and 12&nbsp;weeks. Remaining investigations will be at baseline and 12&nbsp;weeks. Patients
         will be advised to report all symptoms and signs suggestive of toxicity and infection,
         especially sore throat. Patients will continue to have a 2-weekly FBC after 6&nbsp;weeks
         if there are abnormalities on the 6-week FBC that do not warrant withdrawal from the
         study. For patient safety, full blood monitoring will be repeated at 4&nbsp;weeks after
         finishing the study, at week 16.
      </p>
      <h4>Additional safety measures</h4>
      <p style="line-height:160%" class="xfullindent1">1. At each clinical assessment (baseline, 2, 4, 8 and 12&nbsp;weeks and early exit from
         the study) we will collect spontaneously reported adverse effects and also administer
         an adverse effect check list covering 8 key symptoms/signs of MXT toxicity (rash,
         oral ulceration, nausea and vomiting, diarrhea, new or increasing dyspnea, new or
         increasing dry cough, severe sore throat, abnormal bruising). If any of these eight
         symptoms are present MXT will be withheld until the case has been discussed with the
         onsite investigator. In addition, severe sore throat or abnormal bruising will lead
         to an urgent FBC being conducted the result of which will be considered by the investigator
         in reaching a decision on the patient continuing in the trial.
      </p>
      <p style="line-height:160%" class="xfullindent1">2. The routine blood tests at baseline, 2, 4, 6 and 12&nbsp;weeks will be reviewed by the
         site investigator within 4&nbsp;days of being taken and the patient withdrawn from the
         study if any indices give cause for concern (that is are outside pre-specified parameters).
      </p>
      <p style="line-height:160%" class="xfullindent1">3. Our administration of a symptoms checklist and monitoring of FBC, LFTs and renal
         function is similar to monitoring advised in the UK (<a href="http://cks.nice.org.uk/dmards#!scenario:8">http://cks.nice.org.uk/dmards#!scenario:8</a> <a href="http://www.webcitation.org/query.php?url=http://cks.nice.org.uk/dmards#!scenario:8&amp;refdoi=10.1186/1745-6215-16-9" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>).
      </p>
      <p style="line-height:160%" class="xfullindent1">4. Folic acid, 5&nbsp;mg once weekly will be given, not on the same day as MXT, preferably
         the day after 
         					<a name="d75316e1223"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>]. Folic acid reduces toxic effects of MXT and improves continuation of therapy and
         compliance 
         					<a name="d75316e1227"></a><a name="d75316e1229"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a></a>,<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>]. There is also evidence that increasing folate levels improves outcomes in schizophrenia
         
         					<a name="d75316e1233"></a>[<a onclick="LoadInParent('#B27'); return false;" href="#B27">27</a>].
      </p>
      <p style="line-height:160%" class="xfullindent1">5. Given that participating psychiatrists will have little or no experience in prescribing
         MXT, we will ensure that there is an on-call system such that all investigators can
         get immediate expert advice from a physician in Pakistan who is experienced in prescribing
         and monitoring methotrexate.
      </p>
      <p style="line-height:160%" class="xfullindent1">6. MXT will be dispensed 2-weekly throughout the study to limit the supply participants
         have, facilitate monitoring and adherence. The label will state: ‘Take once a week’.
      </p>
      <p style="line-height:160%" class="xfullindent1">7. Participants will all have an information leaflet with safety information.</p>
      <p style="line-height:160%" class="xfullindent1">8. The patients will have access to their RA at all times, who will be able to contact
         the research team medical staff 24&nbsp;hours a day, 7&nbsp;days a week for support and advice.
      </p>
      <h4>Study procedures</h4>
      <h4>Recruitment</h4>
      <p style="line-height:160%">Responsible consultant psychiatrists will be approached and asked if they will allow
         their patients to take part in this research study. The research clinician, initially,
         will approach the clinical teams to inform them about the research study, specifically
         with regard to inclusion and exclusion criteria. The research clinician will establish
         a good working relationship with individual clinical teams. With regular contact,
         either by phone or by visits, patients who are suitable to take part in the research
         study will be identified in collaboration with the treating teams. The consultant
         psychiatrist will then introduce the study to the patient if they meet the inclusion
         criteria, are clinically stable, and the MDT agree the patient could be a possible
         participant. With the patient’s consent, the research clinician will visit them and
         explain the research study verbally as well as provide them with the written information.
         At least 24&nbsp;hours will be given to the patient to allow time to read and understand
         the patient information sheet. If they are willing to take part, a meeting will be
         organised with the patient in order to obtain consent for the research and also consent
         for the research team to have access to their medical notes.
      </p>
      <h4>Screening visit</h4>
      <p style="line-height:160%">At the screening visit a confirmation of a patient’s suitability for the trial will
         be carried out. The patient will be assessed against the inclusion/exclusion criteria,
         have a confirmation of their diagnosis, confirmation of consent to take part in the
         trial and pregnancy testing if appropriate. The RAs will arrange for a doctor to complete
         a checklist for medical history, physical examination and hematological investigations.
      </p>
      <h4>Randomisation visit</h4>
      <p style="line-height:160%">The baseline clinical and neuropsychological measures will be completed and the patient
         will be randomised to one of the two arms, allocated a unique identification number
         and will commence study drug treatment.
      </p>
      <p style="line-height:160%">The patient will be given a study information card explaining that they are in a clinical
         study and are taking MXT or placebo; the telephone numbers of the senior research
         clinicians, the clinical trial office and the name of the local PIs will be provided.
      </p>
      <p style="line-height:160%">In accordance with (International Conference for Harmonisation) Good Clinical Practice
         ((ICH) GCP) (1996) 
         						<a name="d75316e1271"></a>[<a onclick="LoadInParent('#B28'); return false;" href="#B28">28</a>], copies of all the above will be placed in the patient’s medical notes along with
         contact names and telephone numbers.
      </p>
      <h4>Follow-up visits</h4>
      <p style="line-height:160%">The first follow-up visit will be after 2&nbsp;weeks of the randomisation to complete clinical
         assessments. There will be subsequent visits at week 4, 8 and 12. The study drugs
         will be dispensed from the local pharmacy departments. The RAs will collect and deliver
         these to the patient at a previously agreed upon location. This will give the opportunity
         for the research team to closely monitor the patient’s physical and mental health,
         side-effects and compliance.
      </p>
      <p style="line-height:160%">Female patients of childbearing capacity taking part in the clinical trial will have
         a pregnancy test at baseline, 8 and 12&nbsp;weeks. If they should become pregnant during
         the course of the study, they will be withdrawn from the study.
      </p>
      <p style="line-height:160%">During the course of the study the patient’s individual consultant and mental health
         care team will be responsible for their overall care. If any concerns do occur with
         regard to the research study, the research team will be contactable to discuss these
         concerns 24&nbsp;hours a day, 7&nbsp;days a week.
      </p>
      <h4>Final visit</h4>
      <p style="line-height:160%">At this visit all clinical, social, cognitive, physical and hematological assessments
         will be completed. Trial medication will cease.
      </p>
      <p style="line-height:160%">At all visits the patient’s cumulative clinical drug treatment will be updated from
         the case notes.
      </p>
      <h4>Study coordination</h4>
      <p style="line-height:160%">Weekly meetings by local investigators will occur to coordinate the study. The chief
         investigator will conduct 2-weekly tele- and video-conference meeting. The access
         grid facility at the University of Manchester will also be available.
      </p>
      <h4>Patient safety</h4>
      <p style="line-height:160%">Day-to-day care will remain the responsibility of the consultant in charge of the
         patient. However, study related safety concerns will be the responsibility of the
         local PI. The PIs and the co-investigators will be contactable at any time via the
         clinical trials office or/and through the senior research clinicians.
      </p>
      <h4>Patient withdrawal</h4>
      <p style="line-height:160%">Patients may be withdrawn from the treatment study for the following reasons:</p>
      <p style="line-height:160%" class="xfullindent1">1. At their own request.</p>
      <p style="line-height:160%" class="xfullindent1">2. At the discretion of the investigator.</p>
      <p style="line-height:160%" class="xfullindent1">3. If any patients suffers a serious adverse event, or moderate to severe adverse
         drug reaction.
      </p>
      <p style="line-height:160%" class="xfullindent1">4. Any patients who meet the criteria for insufficient compliance. This is defined
         as either taking less than 75% of antipsychotic or trial medication between assessment
         points at baseline, 6&nbsp;weeks and 12&nbsp;weeks; or missing trial medications or antipsychotic
         medication altogether for 7&nbsp;days or more at any period.
      </p>
      <p style="line-height:160%" class="xfullindent1">5. If a patient becomes pregnant.</p>
      <h4>Ethical and regulatory standards</h4>
      <h4><em>Local Research Ethics Committee (LREC)</em></h4>
      <p style="line-height:160%">Ethical approval was obtained from the research and ethics committee of the Pakistan
         Institute of Learning and Living and was submitted to the funding body, Stanley Medical
         Research Institute.
      </p>
      <h4><em>Data and Safety Monitoring Board (DSMB)</em></h4>
      <p style="line-height:160%">The DSMB will be constituted according to NIH guidelines, for oversight and monitoring
         of the conduct of clinical trial. DSMB will meet every 6&nbsp;months to ensure the safety
         of participants and the validity and integrity of the data.
      </p>
      <h4><em>Declaration of Helsinki</em></h4>
      <p style="line-height:160%">The research study will be performed in accordance with the guidelines in the Declaration
         of Helsinki (1974) as revised in Tokyo (1975), Venice (1983), Hong Kong (1989), South
         Africa (1996) and Scotland (2000).
      </p>
      <p style="line-height:160%">All members of the research team will comply with ICH/GCP Guidelines (1996), which
         are consistent with principles that have their origin in the Declaration of Helsinki.
      </p>
      <h4><em>Team expertise</em></h4>
      <p style="line-height:160%">Five of the investigators have extensive experience in treatment and management of
         schizophrenia (Chaudhry, Haddad, Husain, Kazmi, Rahman and Deakin). Kazmi and Rahman
         as local investigators will be important components of success in recruitment. All
         investigators have been closely involved in setting up the methodology and software
         for gathering clinical and research data in patients with psychosis. Chaudhry and
         Husain will oversee the training of RAs in recruiting patients and in diagnostic and
         symptom ratings. All of the investigators were involved in feasibility study for this
         trial. Deakin, Haddad and Chaudhry are experts in psychopharmacology. Chaudhry and
         Husain have been PIs in a number of multicentre trials funded by the Medical Research
         Council (MRC) and SMRI in schizophrenia and have much experience of large-scale treatment
         studies in psychosis. Chaudhry and Husain have published longitudinal studies on negative
         symptoms, cognition and quality of life. Husain, Chaudhry, Kazmi, Rahman and colleagues
         ran the SMRI trial of minocycline.
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia
         and anti-inflammatory treatments have shown to have some beneficial effects. MXT is
         a known immuno-suppressant and anti-inflammatory drug. The aim of the this study is
         to evaluate the effectiveness of MXT added to TAU on positive and negative symptoms,
         cognitive and social functioning and quality of life of patients suffering from schizophrenia.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">This clinical trial was registered in February of 2014. The study is currently recruiting
         participants. The estimated study completion date is December 2015. Please refer to
         this study by its ClinicalTrials.gov identifier: NCT02074319.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">ANCOVA: analysis of covariance; ANNSERS: Antipsychotic Non-Neurological Side-Effects
         Rating Scale; BDNF: brain-derived neurotrophic factor; BMI: body Mass Index; BP: blood
         Pressure; CGI: Clinical Global Impression; CRP: C-reactive protein; DHFR: dihydrofolate
         reductase; DSMB: Data and Safety Monitoring Board; DSM-IV-TR: <em>Diagnostic and Statistical Manual-IV-text revision</em>; ECG: electrocardiogram; FBC: full blood count; GAF: Global Assessment of Functioning;
         GCP: Good Clinical Practice; GEE: generalised estimating equations; ICD-10: <em>International Statistical Classification of Diseases and Related Health Problems</em>; ICH: International Conference for Harmonisation; IFN-gamma: interferon-gamma; IL:
         interleukin; IL-1RA: interleukin 1 receptor antagonist; IQ: Intelligence Quotient,
         ITT, intention-to-treat; LFTs: liver function tests; LREC: Local Research Ethics Committee;
         MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia;
         MDT: multi-disciplinary teams; MRC: Medical Research Council; MXT: methotrexate; NMDA:
         N-methyl-D-aspartate; NO: nitric oxide; PANSS: Positive and Negative Syndrome Scale;
         PET: positron emission tomography; PI: principal investigator; QLS: Quality of Life
         Scale; QOL: quality of life; RA: research assistants; RMO: resident medical officer;
         ROS: reactive oxygen species; SFS: Social Functioning Scale; SCID: Structured Clinical
         Interview for DSM-IV; sIL-2R: soluble IL-2 receptor; SMRI: Stanley Medical Research
         Institute; TAU: treatment as usual; TNF-alpha: tumour necrosis factor-alpha; TRS:
         Treatment Resistant Schizophrenia; UK: United Kingdom; WAIS: Wechsler Adult Intelligence
         Scale.
      </p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">IBC, JFWD, PH and NH have given lectures and advice to Lilly, Bristol Myers Squibb,
         Lundbeck, Astra Zeneca and Janssen pharmaceuticals for which they or their employing
         institution have been reimbursed. None of the companies they have worked with have
         a financial interest in this research. All other authors have no reported conflicts
         of interest.
      </p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">IBC has extensive experience of clinical trials and management of schizophrenia, conceived
         the study, participated in its design and draft the manuscript. NH has extensive experience
         of clinical trials and management of schizophrenia, conceived the study, participated
         in its design and draft the manuscript. RR contributed to design and methodology of
         study, supervision and training of RAs, has extensive experience of clinical trials
         and management of schizophrenia. MOH contributed to design and methodology and writing
         of manuscript. MH contributed to design and methodology of study, supervision and
         training of RAs, has extensive experience of clinical trials and management of schizophrenia.
         AK contributed to design and methodology of study, supervision and training of RAs,
         has extensive experience in management of schizophrenia. SB has extensive experience
         in use of methotrexate, helped conceive the study and is involved in setting up the
         drug related components of trial such as dose, potency, and adverse effect monitoring.
         PMH has extensive experience of clinical trials and management of schizophrenia, contributed
         to design and methodology of the study. MB is clinical trialist of biologic therapies
         and translational research of autoimmune diseases, contributed to design and was closely
         involved in setting up the drug related components of trial like dose, potency, and
         adverse effect monitoring. IQ contributed to design and methodology and writing of
         manuscript. NM contributed to methodology and procedure, was involved in screening,
         recruitment and assessment. TK contributed to methodology and procedure, was involved
         in screening, recruitment and assessment. BF is a biostatistician and is involved
         in designing trial statistical methodology. SA has extensive experience of use of
         methotrexate and contributed to methodology of the study. JFWD has extensive experience
         of clinical trials and management of schizophrenia, conceived the study, participated
         in its design and methodology. All authors read and approved the final manuscript.
      </p>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgments</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">This research was funded by the Stanley Medical Research Institute (SMRI). We would
         like to thank Pakistan Institute of Living and Learning for their logistical support.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a> Cronstein BN: <strong> Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. </strong><p><em>Pharmacol Rev</em> 2005,  <strong>57</strong>(2)<strong>:</strong>163-72.  <a target="_blank" href="/pubmed/15914465">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15914465">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B1" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B1','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Ravi Rajagopalan PT,  Zhang Z,  McCourt L,  Dwyer M,  Benkovic SJ,  Hammes G: <strong> Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule
                  kinetics. </strong><p><em>Proc Natl Acad Sci</em> 2002,  <strong>99</strong>(21)<strong>:</strong>13481-6.  <a target="_blank" href="/pubmed/12359872">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12359872">Publisher&nbsp;Full&nbsp;Text</a> | <a target="_blank" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=12359872">PubMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B2" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Johnston A,  Gudjonsson JE,  Sigmundsdottir H,  Runar Ludviksson B,  Valdimarsson H: <strong> The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis,
                  but by the suppression of activation and adhesion molecules. </strong><p><em>Clin Immunol</em> 2005,  <strong>114</strong>(2)<strong>:</strong>154-63.  <a target="_blank" href="/pubmed/15639649">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15639649">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B3" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Gong K,  Zhang Z,  Sun X,  Zhang X,  Li A,  Yan J,  Luo Q,  Gao Y,  Feng Y: <strong> The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic
                  heart failure. </strong><p><em>Am Heart J</em> 2006,  <strong>151</strong>(1)<strong>:</strong>62-8.  <a target="_blank" href="/pubmed/16368293">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16368293">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B4" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Zhang Z,  Zhao P,  Li A,  Lv X,  Gao Y,  Sun H,  Ding Y,  Liu J: <strong> Effects of methotrexate on plasma cytokines and cardiac remodeling and function in
                  postmyocarditis rats. </strong><p><em>Mediators Inflamm</em> 2009.,  <strong>389720</strong> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B5" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Busse S,  Busse M,  Schiltz K,  Bielau H,  Gos T,  Brisch R,  Mawrin C,  Schmitt A,  Jordan W,  Müller UJ,  Bernstein HG,  Bogerts B,  Steiner J: <strong> Different distribution patterns of lymphocytes and microglia in the hippocampus of
                  patients with residual versus paranoid schizophrenia: further evidence for disease
                  course-related immune alterations? </strong><p><em>Brain Behav Immun</em> 2012,  <strong>26</strong>(8)<strong>:</strong>1273-9.  <a target="_blank" href="/pubmed/22917959">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22917959">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B6" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> Chaudhry IB,  Hallak J,  Husain N,  Minhas F,  Stirling J,  Richardson P,  Dursun S,  Dunn G,  Deakin B: <strong> Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind
                  placebo-controlled clinical trial in patients on standard treatment. </strong><p><em>J Psychopharmacol</em> 2012,  <strong>26</strong>(9)<strong>:</strong>1185-93.  <a target="_blank" href="/pubmed/22526685">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22526685">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B7" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Potvin S,  Stip E,  Sepehry AA,  Gendron A,  Bah R,  Kouassi E: <strong> Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. </strong><p><em>Biol Psychiatry</em> 2008,  <strong>63</strong>(8)<strong>:</strong>801-8.  <a target="_blank" href="/pubmed/18005941">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18005941">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B8" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Mansur RB,  Zugman A,  Asevedo EM,  da Cunha GR,  Bressan RA,  Brietzke E: <strong> Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical
                  and preclinical stages. </strong><p><em>Psychiatry Clin Neurosci</em> 2012,  <strong>66</strong>(4)<strong>:</strong>247-60.  <a target="_blank" href="/pubmed/22624729">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22624729">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B9" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Miller BJ,  Buckley P,  Seabolt W,  Mellor A,  Kirkpatrick B: <strong> Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic
                  effects. </strong><p><em>Biol Psychiatry</em> 2011,  <strong>70</strong><strong>:</strong>663-71.  <a target="_blank" href="/pubmed/21641581">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21641581">Publisher&nbsp;Full&nbsp;Text</a> | <a target="_blank" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=21641581">PubMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B10" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Behrens MM,  Ali SS,  Dugan LL: <strong> Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. </strong><p><em>J Neurosci</em> 2008,  <strong>28</strong><strong>:</strong>13957-66.  <a target="_blank" href="/pubmed/19091984">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19091984">Publisher&nbsp;Full&nbsp;Text</a> | <a target="_blank" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=19091984">PubMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B11" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Schulte-Herbruggen O,  Nassenstein C,  Lommatzsch M,  Quarcoo D,  Renz H,  Braun A: <strong> Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain derived
                  neurotrophic factor in human monocytes. </strong><p><em>J Neuroimmunol</em> 2005,  <strong>160</strong><strong>:</strong>204-9.  <a target="_blank" href="/pubmed/15710474">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15710474">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B12" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Drzyzga L,  Obuchowicz E,  Marcinowska A,  Herman ZS: <strong> Cytokines in schizophrenia and the effects of antipsychotic drugs. </strong><p><em>Brain Behav Immun</em> 2006,  <strong>20</strong>(6)<strong>:</strong>532-45.  <a target="_blank" href="/pubmed/16580814">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16580814">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B13" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Bernstein HG,  Steiner J,  Bogerts B: <strong> Glial cells in schizophrenia: pathophysiological significance and possible consequences
                  for therapy. </strong><p><em>Expert Rev Neurother</em> 2009,  <strong>9</strong><strong>:</strong>1059-71.  <a target="_blank" href="/pubmed/19589054">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19589054">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B14" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Monji A,  Kato T,  Kanba S: <strong> Cytokines and schizophrenia: microglia hypothesis of schizophrenia. </strong><p><em>Psychiatry Clin Neurosci</em> 2009,  <strong>63</strong><strong>:</strong>257-65.  <a target="_blank" href="/pubmed/19579286">PubMed&nbsp;Abstract</a> |  <a target="_blank" href="http://dx.doi.org/10.1111/j.1440-1819.2009.01945.x">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B15" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Myint AM: <strong> Kynurenines: from the perspective of major psychiatric disorders. </strong><p><em>FEBS J</em> 2012,  <strong>2009</strong>(279)<strong>:</strong>1375-85.  <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B16" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Doorduin J,  de Vries EF,  Willemsen AT,  de Groot JC,  Dierckx RA,  Klein HC: <strong> Neuroinflammation in schizophrenia-related psychosis: a PET study. </strong><p><em>J Nucl Med</em> 2009,  <strong>50</strong><strong>:</strong>1801-7.  <a target="_blank" href="/pubmed/19837763">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19837763">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B17" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> van Berckel BN,  Bossong MG,  Boellaard R,  Kloet R,  Schuitemaker A,  Caspers E,  Luurtsema G,  Windhorst AD,  Cahn W,  Lammertsma AA,  Kahn RS: <strong> Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195
                  positron emission tomography study. </strong><p><em>Biol Psychiatry</em> 2008,  <strong>64</strong><strong>:</strong>820-2.  <a target="_blank" href="/pubmed/18534557">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18534557">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B18" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a> Kay SR,  Fiszbein A,  Opler LA: <strong> The positive and negative syndrome scale (PANSS) for schizophrenia. </strong><p><em>Schizophr Bull</em> 1987,  <strong>13</strong><strong>:</strong>261-76.  <a target="_blank" href="/pubmed/3616518">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=3616518">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B19" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B19','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a>American Psychiatric Association: <em>Diagnostic and statistical manual of mental disorders</em>.  4th edition.  Washington, DC: American Psychiatric Association;  2000. <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B20" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Birchwood M, The Social Functioning Scale: <strong> The development and validation of a new scale of social adjustment for use in family
                  intervention programmes with schizophrenic patients. </strong><p><em>Br J Psychiatry</em> 1990,  <strong>157</strong><strong>:</strong>853-9.  <a target="_blank" href="/pubmed/2289094">PubMed&nbsp;Abstract</a> |  <a target="_blank" href="http://dx.doi.org/10.1192/bjp.157.6.853">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B21" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Heinrichs DW,  Hanlon TE,  Carpenter WT: <strong> The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. </strong><p><em>Schizophr Bull</em> 1984,  <strong>10</strong><strong>:</strong>388-98.  <a target="_blank" href="/pubmed/6474101">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=6474101">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B22" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Yusufi BZ,  Mukherjee S,  Aitchison K,  Dunn G,  Page E,  Barnes TR: <strong> Inter-rater reliability of the antipsychotic non-neurological side-effects rating
                  scale (ANNSERS). </strong>In <em>Abstracts of the XX International Congress on Schizophrenia Research, April 2 – April
                  6, 2005, Volume 31</em>.  Savannah, Georgia: Schizophr Bull;  2005:574.  <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B23" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a> Whittle SL,  Hughes RA: <strong> Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. </strong><p><em>Rheumatology</em> 2004,  <strong>43</strong><strong>:</strong>267-71.  <a target="_blank" href="/pubmed/14963199">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14963199">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B24" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Ortiz Z,  Shea B,  Suarez-Almazor ME,  Moher D,  Wells GA,  Tugwell P: <strong> The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal
                  toxicity in rheumatoid arthritis: a meta-analysis of randomised controlled trials. </strong><p><em>J Rheumatol</em> 1998,  <strong>25</strong><strong>:</strong>36-43.  <a target="_blank" href="/pubmed/9458200">PubMed&nbsp;Abstract</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B25" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a> Morgan SL,  Baggott JE,  Vaughn WH,  Austin JS,  Veitch TA,  Lee JY,  Koopman WJ,  Krumdieck CL,  Alarcón GS: <strong> Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis:
                  a double-blind placebo-controlled trial. </strong><p><em>Ann Intern Med</em> 1994,  <strong>121</strong><strong>:</strong>833-41.  <a target="_blank" href="/pubmed/7978695">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=7978695">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B26" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B26','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B27">
            <p><a name="B27"></a> Procter A: <strong> Enhancement of recovery from psychiatric illness by methylfolate. </strong><p><em>Br J Psychiatry</em> 1991,  <strong>159</strong><strong>:</strong>271-2.  <a target="_blank" href="/pubmed/1773245">PubMed&nbsp;Abstract</a> |  <a target="_blank" href="http://dx.doi.org/10.1192/bjp.159.2.271">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=1745-6215-16-9&amp;bibl=B27" onclick="popup('/sfx_links?ui=1745-6215-16-9&amp;bibl=B27','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B28">
            <p><a name="B28"></a><em>Harmonised Tripartite Guideline for Good Clinical Practice 1996 </em> Geneva: International Federation of the Pharmaceutical Manufacturers Association;  1996.</p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/1745/6215/16/9",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

